Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright

Cabaletta Bio, Inc. (NASDAQ:CABA) – Research analysts at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Cabaletta Bio in a research note issued on Wednesday, April 1st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their prior estimate of ($0.47). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.51) EPS, Q4 2027 earnings at ($0.37) EPS, FY2027 earnings at ($1.48) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($0.64) EPS.

A number of other analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday, January 21st. Guggenheim upped their price objective on Cabaletta Bio from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Morgan Stanley dropped their target price on Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 24th. Finally, Wall Street Zen upgraded Cabaletta Bio from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cabaletta Bio presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Cabaletta Bio Stock Up 10.4%

Shares of CABA stock opened at $2.96 on Friday. The company has a market cap of $329.51 million, a P/E ratio of -1.30 and a beta of 3.30. The business has a 50 day moving average of $2.93 and a two-hundred day moving average of $2.58. Cabaletta Bio has a 52 week low of $0.99 and a 52 week high of $3.78.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.05.

Insiders Place Their Bets

In other Cabaletta Bio news, Director Shawn Tomasello acquired 22,725 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was acquired at an average cost of $2.21 per share, with a total value of $50,222.25. Following the acquisition, the director directly owned 22,725 shares of the company’s stock, valued at $50,222.25. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Steve Gavel bought 22,170 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was acquired at an average price of $2.27 per share, for a total transaction of $50,325.90. Following the completion of the transaction, the insider owned 22,170 shares in the company, valued at $50,325.90. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders purchased 127,668 shares of company stock worth $286,211. 11.25% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. increased its holdings in shares of Cabaletta Bio by 17.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company’s stock valued at $21,590,000 after purchasing an additional 1,495,768 shares during the period. Invesco Ltd. lifted its holdings in Cabaletta Bio by 54.1% in the fourth quarter. Invesco Ltd. now owns 189,195 shares of the company’s stock worth $414,000 after purchasing an additional 66,395 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in Cabaletta Bio in the 4th quarter valued at about $58,000. KVP Capital Advisors LP bought a new position in Cabaletta Bio in the 4th quarter valued at about $1,107,000. Finally, Ikarian Capital LLC acquired a new position in Cabaletta Bio during the 4th quarter valued at about $1,971,000.

More Cabaletta Bio News

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised FY2026 EPS from ($1.89) to ($1.51), narrowing expected losses for the year — a meaningful improvement in the near‑term outlook that supports higher valuation multiples for a small biotech. HC Wainwright raises FY2026 estimate
• Positive Sentiment: Quarterly 2026 estimates were also bumped: Q1–Q4 2026 EPS forecasts moved materially less negative (examples: Q1 from ($0.47) to ($0.39); Q2 from ($0.48) to ($0.40); Q3/Q4 to ~$0.36), reducing near‑term cash‑burn/loss expectations. HC Wainwright quarterly updates
• Positive Sentiment: HC Wainwright raised multi‑year outlooks (FY2027, FY2028, FY2029) — e.g., FY2027 from ($1.97) to ($1.48); FY2028 from ($1.86) to ($1.41); FY2029 from ($0.92) to ($0.64) — signaling the analyst sees a clearer path to narrower losses and eventual profitability. HC Wainwright multi-year raises
• Neutral Sentiment: HC Wainwright published forward estimates for 2027–2030 (including a FY2030 EPS of $1.11), which provides a long‑term revenue/profit scenario but depends on successful clinical/regulatory execution — useful for modeling but speculative. HC Wainwright long-term forecast
• Negative Sentiment: Despite the upgrades, consensus and company remain unprofitable this year (consensus FY current ~($2.34)/share) — ongoing clinical, regulatory and cash‑burn risks mean upside from estimate revisions is not guaranteed. Consensus still negative
• Negative Sentiment: Cabaletta is a small, high‑beta biotech (market cap ≈ $330M) so the stock can be volatile; analyst upgrades can spark short‑term rallies but fundamental binary risks (trial readouts, regulatory news, financing) remain primary drivers. Risk/volatility context

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.